AstraZeneca has secured a conditional marketing authorisation for its Covid-19 vaccine in the European Union (EU) for active immunisation in individuals aged 18 years and above.
Dr. Reddy's Laboratories has agreed to collaborate with the Russian Direct Investment Fund (RDIF) to conduct clinical trials and supply Sputnik V vaccine for Covid-19 in India.
Merck announced the US launch of ONTRUZANT (trastuzumab-dttb), as a biosimilar of the reference biologic medicine Herceptin.
Shionogi announced FETROJA (cefiderocol) is now available in the U.S. for patients 18 years of age or older who have limited or no alternative treatment options, for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis, caused by the following susceptible Gram-negative microorganisms: Escherichia coli (E. coli), Klebsiella pneumoniae (K. pneumoniae), Proteus mirabilis (P. mirabilis), Pseudomonas aeruginosa (P. aeruginosa), and Enterobacter cloacae (E. cloacae) complex.
The products are now a part of Armas' consistently growing product line, bringing their portfolio count to eleven
Sun Pharmaceutical Industries announced that one of its wholly owned subsidiaries has launched Drizalma Sprinkle (duloxetine delayed-release capsules) in the US for oral use.
Kyowa Kirin, Inc. (Kyowa Kirin), an affiliate of Kyowa Kirin Co., Ltd. (TSE: 4151), announced today that NOURIANZ (istradefylline) is now available in the U.S. as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson’s disease (PD) experiencing “off” episodes.
Sun Pharmaceutical Industries announced that one of its wholly-owned subsidiaries has commercialised CEQUA (cyclosporine ophthalmic solution) 0.09% in the US.
Celltrion announced that it is launching Temixy in the US, which were approved in November by US Food and Drug Administration (FDA).
Gilead Sciences Canada announced that effective July 31, the Ontario Drug Benefit Program will provide eligible patients with access to Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg) tablets, a once-daily single tablet and complete regimen for the treatment of HIV-1 infection in adults. Health Canada granted a Notice of Compliance for BIKTARVY in July 2018.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.